The MMDN lab (group "Cellular deterlminants of neuroprotection") is proposing a 2.5-year postdoctoral fellowship, funded by ANR and DFG, for an highly motived and competitive young researcher.
SIR-BUCHE-AD is a collaborative project is a collaboration between the group of Michael Decker (University of Würzburg; medicinal chemistry), the group of Tangui Maurice (MMDN; neuropharmacology) and the group of Tsung-Ping Su (NIDA, NIH, Baltimore; cellular biology). Novel photoswitchable sigma-1 receptor (S1R) agonists and antagonists will be synthetized and used to examine S1R-dependent cellular pathways (autophagy, neurite pruning, axonal transport of vesicles and mitochondria). Hybrid sigma-1 agonists and butyrylcholinesterase inhibitors will be designed as novel neuroprotective agents in muring models of Alzheimer's disease.
